Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 17/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 10/20 | 0.50 |
| ▸ | MAOB | P27338 | 10/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30562191 | 1.00 | ALDH2 (0.54) | ALDH2ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL29434200 | 1.00 | ALDH2 (0.54) | ALDH2ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL2107625 | 0.92 | ALDH2 (0.52) | ALDH2ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL2107782 | 0.92 | ALDH2 (0.51) | ALDH2ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL2107287 | 0.90 | ALDH2 (0.53) | ALDH2ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL2109208 | 0.90 | ALDH2 (0.51) | ALDH2ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL2110736 | 0.90 | ALDH2 (0.49) | ALDH2ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL2110738 | 0.89 | ALDH2 (0.49) | ALDH2ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL2107964 | 0.89 | ALDH2 (0.53) | ALDH2ALDH1A1MAPTMAOAMAOB | |
| SCHEMBL2110415 | 0.88 | ALDH2 (0.53) | ALDH2ALDH1A1MAPTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220117916-A1 | Combination Products to Mitigate the Risk of Non-Benzodiazepine Benzodiazepine Agonist Adverse Reaction and Overdose | SAFERX PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | US | claimed |
| CN-113543777-A | Pharmaceutical composition for preventing or treating acidosis | 哈林生物有限公司 | 2021-10-22 | — | — | CN | claimed |
| CN-113382727-A | Pharmaceutical composition for administration in combination with acidosis-causing drug | 哈林生物有限公司 | 2021-09-10 | — | — | CN | claimed |
| WO-2021141425-A1 | PHARMACEUTICAL COMPOSITION, FOR PREVENTING AND TREATING HEMATOLOGICAL CANCER, COMPRISING BIGUANIDE-BASED COMPOUND AS ACTIVE INGREDIENT | 주식회사 하임바이오 | 2021-07-15 | — | — | WO | claimed |
| US-20210161835-A1 | Combination Treatments for Opioid Crisis | PRESTI MICHAEL (US) | 2021-06-03 | — | — | US | claimed |
| US-10881625-B2 | Combination treatments for opioid crisis | PRESTI MICHAEL (US) | 2021-01-05 | — | — | US | claimed |
| WO-2020213939-A1 | PHARMACEUTICAL COMPOSITION FOR CO-ADMINISTRATION OF ANTICANCER DRUG | 주식회사 진센 | 2020-10-22 | — | — | WO | claimed |
| WO-2020213938-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING SAPONIN AS ACTIVE INGREDIENT | 주식회사 진센 | 2020-10-22 | — | — | WO | claimed |
| US-10478408-B2 | Combination treatments for opioid crisis | PRESTI MICHAEL (US) | 2019-11-19 | — | — | US | claimed |
| US-20190231719-A1 | COMBINATION TREATMENTS FOR OPIOID CRISIS | PRESTI MICHAEL (US) | 2019-08-01 | — | — | US | claimed |
| EP-2254878-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | Gilead Palo Alto, Inc. (US) | 2010-12-01 | — | — | EP | claimed |
| EP-2231149-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV Therapeutics Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2009-08-20 | — | — | US | claimed |
| WO-2009094028-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-07-30 | — | — | WO | claimed |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | AMYGDALA NEUROSCIENCES, INC. | 2009-05-14 | — | — | US | claimed |
| WO-2009061924-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | CV THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | WO | claimed |
| EP-2046769-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-08-28 | — | — | US | claimed |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | AMYGDALA NEUROSCIENCES, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2008014497-A2 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | CV THERAPEUTICS, INC. (US) | 2008-01-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207610-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 5/4885ALDH1A1 1/4885MAPT 1815/4885 |
| US-20090209533-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 5/4885ALDH1A1 1/4885MAPT 1815/4885 |
| US-20080032995-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF DRUG ADDICTION | ALDH1A1, ADH1A, ALDH3A1 | ALDH2 4/4885ALDH1A1 1/4885MAPT 1778/4885 |
| US-20090124672-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF PSYCHIATRIC DISORDERS | ALDH2, ALDH1A2, ALDH1A1 | ALDH2 1/4885ALDH1A1 3/4885MAPT 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.